StocksMedium•4 November 2026•
1 min read
Harmony Biosciences Reports $269M Q3 WAKIX Revenue, Reaffirms Guidance
Key Facts
1Harmony Biosciences reported Q3 WAKIX net revenue of $269 million.
2The company reiterated its full-year revenue guidance of $1.0 billion to $1.04 billion.
3The company announced strong multiple-ascending dose data for its orexin agonist BP-205.
Harmony Biosciences reported WAKIX net revenue of $269 million for the third quarter of 2026, according to GlobeNewswire. The company reiterated its full-year revenue guidance of $1.0 billion to $1.04 billion, supported by 400 net patient additions during the quarter.
The company also announced strong multiple-ascending dose data for its innovative orexin agonist, BP-205. Regarding market performance, HRMY closed at $37.02 on November 3, 2026, having traded between a session low of $36.33 and a high of $38.75.